| 2026-08-18 | Press release | Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions |
| 2026-08-18 | Press release | Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary |
| 2026-08-05 | Press release | BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance |
| 2026-08-05 | Deck | Investor presentation · Q2 2026 · Aug 2026 |
| 2026-08-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-05 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-20 | Press release | BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar |
| 2026-07-15 | Press release | BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026 |
| 2026-07-15 | Press release | Press ReleasesJuly 15, 2026BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026Read Article |
| 2026-06-29 | Press release | BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for C |
| 2026-06-29 | Press release | Press ReleasesJune 29, 2026BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Sta |
| 2026-06-29 | 8-K | Form 8-K, Item 1.01 |
| 2026-06-16 | 8-K | Form 8-K, Item 1.01 |
| 2026-05-27 | Press release | BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference |
| 2026-05-27 | Press release | Press ReleasesMay 27, 2026BillionToOne to Participate in the William Blair 46th Annual Growth Stock ConferenceRead Artic |
| 2026-05-06 | Press release | BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance |
| 2026-05-06 | Deck | Investor presentation · Q1 2026 · May 2026 |
| 2026-05-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-06 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-01 | Press release | BillionToOne Launches Unity Confirm™: A category-defining test that bridges the gap between screening and invasive diagn |
| 2026-04-21 | Proxy | Definitive proxy statement |
| 2026-04-15 | Press release | BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026 |
| 2026-04-15 | Press release | Press ReleasesApril 15, 2026BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026Read Article |
| 2026-04-02 | Press release | BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology |
| 2026-03-11 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-07 | Transcript | Q4 FY25 earnings call transcript |
| 2026-03-04 | Deck | Earnings presentation · FY 2025 · Mar 2026 |
| 2026-03-04 | Press release | Press ReleasesMarch 4, 202620262026BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenu |
| 2026-03-04 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-17 | Press release | BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 |
| 2026-02-17 | Press release | Press ReleasesFebruary 17, 2026BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 20 |
| 2026-02-10 | Press release | BillionToOne Expands Northstar Platform with Launch of Two New Add-On Liquid Biopsy Applications for Northstar Select® |
| 2026-02-10 | Document | CAP: 8643216 |
| 2026-01-15 | Press release | BillionToOne Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Across Healthcare |
| 2026-01-15 | Press release | Press ReleasesJanuary 15, 2026BillionToOne Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Acr |
| 2026-01-12 | Press release | BillionToOne Provides Guidance for 2026 |
| 2026-01-12 | 8-K | Form 8-K, Item 2.02 results |
| 2025-12-23 | Press release | BillionToOne to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 2025-12-15 | Transcript | Q3 FY25 earnings call transcript |
| 2025-12-10 | 10-Q | Form 10-Q for the quarter ended Sep 30 |